Overview A Study to Evaluate the Safety and Efficacy of Prograf/FK778 and Prograf/MMF in de Novo Kidney Transplant Recipients Status: Terminated Trial end date: 2005-10-01 Target enrollment: Participant gender: Summary A study to evaluate the safety and efficacy of Prograf/FK778 in de novo kidney transplant patients Phase: Phase 2 Details Lead Sponsor: Astellas Pharma IncCollaborator: Astellas Pharma US, Inc.Treatments: Tacrolimus